GlassScriptPhysician profile
Emad H Daniel
NPI 1205034287
$1,153.19
in general payments reported to CMS, 2019-2025
10 companies · $77.77 in 2025
The $77.77 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $185 · 2021: $103 · 2022: $95.49 · 2023: $122 · 2024: $423 · 2025: $77.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $225.80 | 2019-2024 | Aristada, Aristada Initio, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.91 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $145.04 | 2024 | Uzedy |
| Sunovion Pharmaceuticals INC. | $136.63 | 2019-2020 | |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Indivior INC. | $114.30 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $100.60 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $82.26 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Luye Pharma (USA) LTD. | $51.89 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $22.76 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.